In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

How the new ESC Guidelines on cardiomyopathies will change my practice?

ESC webinar

26/11/2014 00:00 26/11/2014 00:00 Europe/Paris How the new ESC Guidelines on cardiomyopathies will change my practice?

Access event page

European Society of Cardiology DD/MM/YYYY
Myocardial Disease
Congenital Heart Disease and Pediatric Cardiology

Part 1: Diagnosis and management of hypertrophic cardiomyopathy


Part 2: Prevention of Complications


Speaker: Perry Elliott (UK)
Moderator: Giuseppe Limongelli (IT)

Our two experts discuss the implementation of the latest ESC Guidelines on Hypertrophic cardiomyopathies into daily practice through clinical cases: Diagnosis and management of hypertrophic cardiomyopathy and Prevention of complications


The faculty will discuss the following issues:

  • Update the audience on  the diagnosis of hypertrophic cardiomyopathies (HCM).  
  • How to apply the recent ESC guidelines on
    HCM in clinical practice.
  • How to estimate the 5 years risk of sudden death in patients with HCM.
  • Understand the principles behind the management of heart failure symptoms in patients with HCM

Learn more by reading the "Questions and Answers" with comments from our experts.

The ESC Webinars are designed to help you improve your daily practice!

The format includes a case based presentation, online assessment and live discussions with the 2 key opinion leaders who will give you some useful tips for your daily clinical practice.


Your questions answered by the experts




This programme is supported by Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb and Pfizer Alliance, Daiichi Sankyo Europe GmbH, Novartis Pharma AG and Servier in the form of unrestricted educational grants.  The scientific programme has not been influenced in any way by its sponsors.